Ekrem AKSU, Abdullah SÖKMEN, Gülizar SÖKMEN, Enes ÇELİK, Hakan GÜNEŞ, Sami ÖZGÜL, Ahmet Çağrı AYKAN, Akif Serhat BALCIOĞLU

Predictors of mortality after transcatheter aortic valve implantation

Aim: Transcatheter aortic valve implantation has been used widely as an alternative treatment method for patients with symptomaticaortic stenosis carrying high surgical risk. Despite technological advances and increased experience, its early and late mortality rateis still relatively high and it is important to predict upcoming cardiac events and mortality for the management of patients. In thisstudy, we aimed to investigate the clinical and laboratory parameters affecting mortality after these procedures performed in ourclinic.Material and Methods: The patients who underwent TAVI due to severe AS between May 2015 and March 2019 were investigatedretrospectively. Demographic, echocardiographic and laboratory data of all patients were recorded. During the follow-up period(mean: 556 days), patients were divided into 2 groups; deceased patients (group 1, n=13) and living patients (group 2, n=34). Thedata of the patients before TAVI procedure were compared between the two groups.Results: Among demograhic data, the ratio of chronic kidney disease was significantly higher in the deceased group. Among echoparameters, left ventricular ejection fraction was significantly lower and pulmonary artery pressure was significantly higher in thedeceased group. Of laboratory parameters, blood urea nitrogen and creatinine levels were significantly higher and toral protein levelswere significantly lower in the deceased group. Additionally, leukocyte, uric acid, CRP and CRP/albumin ratio were significantlyhigher and albumin was significantly lower in the deceased patients.Conclusion: The presence of chronic kidney disease, low left ventricular EF, high pulmonary artery pressure, high CRP levels, increasedCRP/albumin ratio and high uric acid levels preceding TAVI may be helpful to determine the risk of mortality after the TAVI procedure.

PDF

___

1. Stewart BF, Siscovick D, Lind BK, et al. Clinical factors associated with calcific aortic valve disease. Cardiovascular Health Study. J Am Coll Cardiol 1997;29:630-4.
2. Nkomo VT, Gardin JM, Skelton TN, et al. Burden of valvular heart diseases: a population- based study. Lancet 2006;368:1005-11.
3. Osnabrugge RL, Mylotte D, Head SJ, et al. Aortic stenosis in the elderly: disease prevalence and number of candidates for transcatheter aortic valve replacement: a metaanalysis and modeling study. J. Am. Coll. Cardiol 2013;62:1002-12.
4. Leon MB, Smith CR, Mack MJ, et al. Transcatheter or surgical aortic-valve replacement in intermediate-risk patients. N Engl J Med 2016;374:1609-20.
5. Holmes DR Jr, Brennan JM, Rumsfeld JS, et al. Clinical outcomes at 1 year following transcatheter aortic valve replacement. JAMA 2015;313:1019-28.
6. Ruparelia N, Panoulas VF, Frame A, et al. Impact of clinical and procedural factors upon C reactive protein dynamics following transcatheter aortic valve implantation World J Cardiol 2016;26;8:425-31.
7. Leon MB, Smith CR, Mack M, et al. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med 2010;363:1597–607.
8. Tamburino C, Capodanno D, Ramondo A, et al. Incidence and predictors of early and late mortality after transcatheter aortic valve implantation in 663 patients with severe aortic stenosis. Circulation 2011;123:299-308.
9. Rodés-Cabau J, Webb JG, Cheung A, et al. Longterm outcomes after transcatheter aortic valve implantation: insights on prognostic factors and valve durability from the Canadian multicenter experience J Am Coll Cardiol 2012;60:1864–75.
10. Michael JR, David H Adams, Neal S. Kleiman, et al. 2-Year outcomes in patient undergoing surgical or self-expanding transcatheter aortic valve replacement. JACC 2015;66:113-21.
11. Dönmez Y, Örsan DU, Kurt İH. T wave positivity in lead aVR is associated with mortality after transcatheter aortic valve implantation. Arch Med Sci Atheroscler Dis 2019;e55-e62.
12. Rheude T, Pellegrini C, Michel J, et al. Prognostic impact of anemia and iron-deficiency anemia in a contemporary cohort of patients undergoing transcatheter aortic valve implantation. Int J Cardiol 2017;244:93-9.
13. Gotzmann M, Pljakic A, Bojara W, et al. Transcatheter aortic valve implantation in patients with severe symptomatic aortic valve stenosis-predictors of mortality and poor treatment response. Am Heart J 2011;162:238-45.
14. Buja P, Napodano M, Tamburino C, et al. Comparison of variables in men versus women undergoing transcatheter aortic valve implantation for severe aortic stenosis (from italian multicenter corevalve registry). Am J Cardiol 2013;111:88-93.
15. Gaglia MA Jr, Lipinski MJ, Torguson R, et al. Comparison in men versus women of co-morbidities, complications, and outcomes after transcatheter aortic valve implantation for severe aortic stenosis. Am J Cardiol 2016;118:1692-97.
16. Saad M, Nairooz R, Pothineni NVK, et al. Long-term outcomes with transcatheter aortic valve replacement in women compared with men evidence from a metaanalysis. JACC Cardiovasc Interv 2018;11:24-35.
17. O’Connor SA, Morice MC, Gilard M, et al. Revisiting sex equality with transcatheter aortic valve replacement outcomes: a collaborative, patient-level meta-analysis of 11,310 patients. J Am Coll Cardiol 2015;66:221-8.
18. Iung B, Baron G, Butchart EG, et al. A prospective survey of patients with valvular heart disease in europe: the euro heart survey on valvular heart disease. Eur Heart J 2003;24:1231-43.
19. Oury C, Nchimi A, Lancellotti P, et al. Can blood biomarkers help predicting outcome in transcatheter aortic valve implantation? Front Cardiovasc Med 2018;5:31.
20. Tarantini G, Mojoli M, Windecker S, et al. Prevalence and impact of atrial fibrillation in patients with severe aortic stenosis undergoing transcatheter aortic valve replacement: an analysis from the SOURCE XT Prospective Multicenter Registry. JACC Cardiovasc Interv 2016;9:937-46.
21. Smith CR, Leon MB, Mack MJ, et al. Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl JMed 2011;364: 2187-98.
22. Moat NE, Ludman P, de Belder MA, et al. Long-term outcomes after transcather aortic valve implantation in high-risk patients with severe aortic stenosis: the UK TAVI (United Kingdom Transcatheter Aortic Valve Implantation) Registry. J Am Coll Cardiol 2011;58:2130–8.
23. Dumont E, Osten M, Feindel CM, et al. Longterm outcomes after transcatheter aortic valve implantation: insights on prognostic factors and valve durability from the Canadian multicenter experience. J Am Coll Cardiol 2012;60:1864-75.
24. Sinning JM, Ghanem A, Steinhauser H, et al. Renal function as predictor of mortality after percutaneous transcatheter aortic valve implantation. JACC Cardiovasc Interv 2010;3:1141-9.
25. Dvir D, Waksman R, Barbash IM, et al. Outcomes of Patients With Chronic Lung Disease and Severe Aortic Stenosis Treated With Transcatheter Versus Surgical Aortic Valve Replacement or Standard Therapy Insights From the PARTNER Trial (Placement of AoRTic TraNscathetER Valve) JACC 2014;63:269-79.
26. Thourani VH, Keeling WB, Sarin EL, et al. Impact of preoperative renal dysfunction on long-term survival for patients undergoing aortic valve replacement. Ann Thorac Surg 2011;91:1798-806.
27. Goebel N, Baumbach H, Ahad S, et al. Transcatheter aortic valve replacement: does kidney function affect outcome? Ann Thorac Surg 2013;96:507-12.
28. Ifedili AI, Bolorunduro O, Bob-Manuel1 T, et al. Impact of Pre-existing Kidney Dysfunction on Outcomes following transcatheter aortic valve replacement Current Cardiology Reviews 2017;13:283-92.
29. Allende R, Webb JG, Munoz-Garcia AJ, et al. Chronic kidney disease in patients undergoing transcatheter aortic valve implantation: insights on clinical outcomes and prognostic markers from a large cohort of patients. Eur Heart J 2014;35:2685-96.
30. Van Linden A, Kempfert J, Rastan AJ, et al. Risk of acute kidney injury after minimally invasive transapical aortic valve implantation in 270 patients. Eur J Cardiothorac Surg 2011;39:835-42.
31. Thourani VH, Forcillo J, Beohar N, et al. Impact of preoperative chronic kidney disease in 2,531 highrisk and inoperable patients undergoing transcatheter aortic valve replacement in the partner trial Ann Thorac Surg 2016;102:1172-80.
32. Sinning JM, Wollert KC, Sedaghat A, et al. Risk scores and biomarkers for the prediction of 1-year outcome after transcatheter aortic valve replacement. Am Heart J 2015;170:821-9.
33. Schewel D, Frerker C, Schewel J, et al. Clinical impact of paravalvular leaks on biomarkers and survival after transcatheter aortic valve implantation. Catheter Cardiovasc Interv 2015;85:502-14.
34. Schmid J, Stojakovic T, Zweiker D, et al. ST2 predicts survival in patients undergoing transcatheter aortic valve implantation. Int J Cardiol 2017;244:87-92.
35. Çınar T, Çağdaş M, Rencüzoğulları İ, et al. Prognostic efficacy of C-reactive protein/albumin ratio in ST elevation myocardial infarction. Scandinavian Cardiovascular J 2019;53:83-90.
36. Kleber ME, Delgado G, Gramer TB, et al. Uric acid and cardiovascular events: a mendelian randomization study. J Am Soc Nephrol 2015;26:2831-38.
37. Zhao G, Huang L, Song M, et al. Baseline serum uric acid level as a predictor of cardiovascular disease related mortality and all-cause mortality: A metaanalysis of prospective studies. Atherosclerosis 2013;231:61-8.
38. Meisinger C, Koenig W, Baumert J, et al. Uric acid levels are associated with all-cause and cardiovascular disease mortality independent of systemic inflammation in men from the general population: TheMONICA/KORA cohort study. Arterioscler Thromb Vasc Biol 2008;28:1186-92.